JP7638935B2 - 抗ｃｃｒ８抗体 - Google Patents

抗ｃｃｒ８抗体 Download PDF

Info

Publication number
JP7638935B2
JP7638935B2 JP2022119632A JP2022119632A JP7638935B2 JP 7638935 B2 JP7638935 B2 JP 7638935B2 JP 2022119632 A JP2022119632 A JP 2022119632A JP 2022119632 A JP2022119632 A JP 2022119632A JP 7638935 B2 JP7638935 B2 JP 7638935B2
Authority
JP
Japan
Prior art keywords
ccr8
antibody
antibodies
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022119632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023018678A5 (enExample
JP2023018678A (ja
Inventor
ジュリー・エル・ウィルスバチャール
アマンダ・エム・シュミット・ポースチャン
ジェーン・シーガル
アンドリュー・ジェイ・マクラスキー
Original Assignee
アッヴィ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・インコーポレイテッド filed Critical アッヴィ・インコーポレイテッド
Publication of JP2023018678A publication Critical patent/JP2023018678A/ja
Publication of JP2023018678A5 publication Critical patent/JP2023018678A5/ja
Priority to JP2025023976A priority Critical patent/JP2025081477A/ja
Application granted granted Critical
Publication of JP7638935B2 publication Critical patent/JP7638935B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022119632A 2021-07-27 2022-07-27 抗ｃｃｒ８抗体 Active JP7638935B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023976A JP2025081477A (ja) 2021-07-27 2025-02-18 抗ｃｃｒ８抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27
US63/226,118 2021-07-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023976A Division JP2025081477A (ja) 2021-07-27 2025-02-18 抗ｃｃｒ８抗体

Publications (3)

Publication Number Publication Date
JP2023018678A JP2023018678A (ja) 2023-02-08
JP2023018678A5 JP2023018678A5 (enExample) 2024-09-09
JP7638935B2 true JP7638935B2 (ja) 2025-03-04

Family

ID=82898810

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022119632A Active JP7638935B2 (ja) 2021-07-27 2022-07-27 抗ｃｃｒ８抗体
JP2025023976A Pending JP2025081477A (ja) 2021-07-27 2025-02-18 抗ｃｃｒ８抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023976A Pending JP2025081477A (ja) 2021-07-27 2025-02-18 抗ｃｃｒ８抗体

Country Status (27)

Country Link
US (1) US11639393B2 (enExample)
EP (2) EP4214240B1 (enExample)
JP (2) JP7638935B2 (enExample)
KR (2) KR20250135339A (enExample)
CN (1) CN117425677A (enExample)
AR (1) AR126578A1 (enExample)
AU (1) AU2022317803A1 (enExample)
BR (1) BR112023024837A2 (enExample)
CA (1) CA3220121A1 (enExample)
CO (1) CO2023015915A2 (enExample)
DK (1) DK4214240T3 (enExample)
ES (1) ES2995868T3 (enExample)
FI (1) FI4214240T3 (enExample)
HR (1) HRP20241561T1 (enExample)
HU (1) HUE069018T2 (enExample)
IL (2) IL319478A (enExample)
LT (1) LT4214240T (enExample)
MX (1) MX2023014154A (enExample)
PL (1) PL4214240T3 (enExample)
PT (1) PT4214240T (enExample)
RS (1) RS66234B1 (enExample)
SA (1) SA523451582B1 (enExample)
SI (1) SI4214240T1 (enExample)
SM (1) SMT202400483T1 (enExample)
TW (1) TW202321304A (enExample)
WO (1) WO2023010054A1 (enExample)
ZA (1) ZA202309516B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
TW202430550A (zh) 2022-10-18 2024-08-01 日商明治製菓藥業股份有限公司 Ｔ細胞性腫瘤之治療劑
TW202448461A (zh) 2023-02-06 2024-12-16 德商拜耳廠股份有限公司 Dgk（二醯基甘油激酶）抑制劑及免疫檢查點抑制劑及調節劑之組合
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
WO2021142002A1 (en) 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CA3023980A1 (en) 2016-05-16 2017-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
KR102144658B1 (ko) * 2017-03-29 2020-08-14 시오노기세이야쿠가부시키가이샤 암 치료용 의약 조성물
TWI832035B (zh) * 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
EP4114862A4 (en) 2020-03-05 2024-07-03 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
MX2022011701A (es) 2020-03-23 2022-10-07 Bristol Myers Squibb Co Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer.
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
MX2023002511A (es) 2020-08-28 2023-04-20 Harbour Biomed Us Inc Anticuerpo anti-ccr8 y aplicacion del mismo.
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
MX2023004349A (es) 2020-10-16 2023-08-22 Lanova Medicines Ltd Anticuerpos monoclonales anti-ccr8 y sus usos.
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
WO2021142002A1 (en) 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof

Also Published As

Publication number Publication date
SA523451582B1 (ar) 2025-04-26
KR20240067052A (ko) 2024-05-16
PT4214240T (pt) 2024-11-25
CN117425677A (zh) 2024-01-19
KR102860769B1 (ko) 2025-09-18
IL307533B1 (en) 2025-04-01
FI4214240T3 (fi) 2024-11-14
DK4214240T3 (da) 2024-11-18
JP2023018678A (ja) 2023-02-08
KR20250135339A (ko) 2025-09-12
MX2023014154A (es) 2024-05-14
IL307533A (en) 2023-12-01
ZA202309516B (en) 2025-03-26
PL4214240T3 (pl) 2025-01-07
LT4214240T (lt) 2024-11-25
JP2025081477A (ja) 2025-05-27
WO2023010054A1 (en) 2023-02-02
AU2022317803A1 (en) 2023-10-26
US11639393B2 (en) 2023-05-02
IL319478A (en) 2025-05-01
CO2023015915A2 (es) 2023-12-11
SMT202400483T1 (it) 2025-01-14
IL307533B2 (en) 2025-08-01
HUE069018T2 (hu) 2025-02-28
EP4214240A1 (en) 2023-07-26
EP4491635A3 (en) 2025-04-02
RS66234B1 (sr) 2024-12-31
TW202321304A (zh) 2023-06-01
EP4491635A2 (en) 2025-01-15
CA3220121A1 (en) 2023-02-02
BR112023024837A2 (pt) 2024-02-20
SI4214240T1 (sl) 2025-02-28
US20230048553A1 (en) 2023-02-16
AR126578A1 (es) 2023-10-25
HRP20241561T1 (hr) 2025-02-14
EP4214240B1 (en) 2024-10-09
ES2995868T3 (en) 2025-02-11

Similar Documents

Publication Publication Date Title
JP7638935B2 (ja) 抗ｃｃｒ８抗体
JP6903188B2 (ja) Ｂｃｍａに対するモノクローナル抗体
CN111138542B (zh) 双特异性抗体及其用途
EP3464367B1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US11660340B2 (en) Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11505605B2 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
JP2016508496A (ja) Ｂｃｍａに対する抗体の選択のための方法
JP2019530661A (ja) Ｃｄ２０抗体
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
JP2025525438A (ja) 自己免疫性疾患、アレルギー性疾患、及び炎症性疾患を治療するための方法及び組成物
HK40100657B (en) Anti-ccr8 antibodies
HK40100657A (en) Anti-ccr8 antibodies
BR122024013309B1 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos
BR122025022218A2 (pt) Anticorpo anti-ccr8 e composição farmacêutica
BR122024013309A2 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos
WO2025083273A1 (en) Binding molecules
CN121127496A (zh) 抗Vβ17/抗CD123双特异性抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240830

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250219

R150 Certificate of patent or registration of utility model

Ref document number: 7638935

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150